ArticleThe oncologist2026

Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes".

Joshua Richter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.